United States, MA – Vaccine Developer Moderna Inc. has asked sites to cater to at-risk minorities during their clinical trials for the experimental COVID-19 vaccine they are working on even if it slows down the trial testing speed.
The company’s shares closed down at about 3.5 % as it was developing a safe and effective COVID-19 vaccine being one of the companies already at the final stages of development.
Communities of color were focused in these tests as 21,411 participants had enrolled with 4080 out of 17,000 participants of the following week being from at-risk minorities.
This month, the expected enrollment for the late stage study was said to have recruited 30,000 healthy volunteers as projected by Moderna in it’s attempt to finalize the vaccine development.
Reports stated that due to long-standing health and social inequities has brought about the increase of danger in communities of color with a high risk of infections and even death.
Trial tests were held by Pfizer and BioNTech to gather data from their 30,000 volunteer drive where it was reported that a large majority of 2200 from 11,000 people who enrolled were from Black and Latino communities where COVID-19 had hit hardest among at-risk minorities.
According to Moderna, the vaccination drive was created with very specific endpoints in order to stave of COVID-19’s rise in numbers with the primary endpoint being prevention of symptomatic COVID-19 disease along with the prevention of severe COVID-19 and SARS-CoV2 virus that kick starts the COVID-19 infections.
The National Institute of Allergy and Infectious Diseases will be working closely with Moderna as they go through these trials.
The race of the fastest vaccine development was something Moderna had sidelined as it went for a more systematic approach to fixing the problem over being the fastest to be available out in the market.
Novovax, a collaboration between the University of Oxford and AstraZeneca along with one vaccine in the race of the first US Vaccine to be pushed out in 2021 from Johnson & Johnson is heavily in line with taking over the market under the U.S government’s Operation Warp Speed where Moderna had beaten them by being the first U.S vaccine to enter phase 3 trials.
30,000 healthy volunteers have stepped up for each company to test which vaccine would be the most successful and rolled out by the start of next year.
